229 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
8021917	84	Three-dimensional pharmacophores from binding data.	Ciba-Geigy
11087569	37	Computational studies on HIV-1 protease inhibitors: influence of calculated inhibitor-enzyme binding affinities on the statistical quality of 3D-QSAR CoMFA models.	University of Missouri St. Louis
9526559	49	Comparative binding energy analysis of HIV-1 protease inhibitors: incorporation of solvent effects and validation as a powerful tool in receptor-based drug design.	Universidad De Alcal£
15993582	19	Hydrophobicity in the design of P2/P2' tetrahydropyrimidinone HIV protease inhibitors.	Clarkson University
10956210	85	DoMCoSAR: a novel approach for establishing the docking mode that is consistent with the structure-activity relationship. Application to HIV-1 protease inhibitors and VEGF receptor tyrosine kinase inhibitors.	Eli Lilly
8523405	176	3D-quantitative structure-activity relationships of human immunodeficiency virus type-1 proteinase inhibitors: comparative molecular field analysis of 2-heterosubstituted statine derivatives-implications for the design of novel inhibitors.	Sandoz Forschungsinstitut Ges.M.B.H.
8035428	30	Three-dimensional quantitative structure-activity relationship of human immunodeficiency virus (I) protease inhibitors. 2. Predictive power using limited exploration of alternate binding modes.	Washington University
8277496	77	Three-dimensional QSAR of human immunodeficiency virus (I) protease inhibitors. 1. A CoMFA study employing experimentally-determined alignment rules.	Washington University
12419382	51	Six-membered cyclic ureas as HIV-1 protease inhibitors: a QSAR study based on CODESSA PRO approach. Quantitative structure-activity relationships.	University of Florida
	25	Synthesis and antiviral activity of a novel class of HIV-1 protease inhibitors containing a heterocyclic P1-P2 amide bond isostere	TBA
17964171	3	Stereocontrolled synthesis and biological activity of two diastereoisomers of the potent HIV-1 protease inhibitor saquinavir.	Sapienza University of Rome
16458505	2	Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385.	Glaxosmithkline
16509598	22	Microwave-accelerated synthesis of P1'-extended HIV-1 protease inhibitors encompassing a tertiary alcohol in the transition-state mimicking scaffold.	Uppsala University
15771466	46	Development of low molecular weight HIV-1 protease dimerization inhibitors.	Purdue University
15537350	54	Improved structure-activity relationship analysis of HIV-1 protease inhibitors using interaction kinetic data.	Uppsala University
15261290	19	A unidirectional crosslinking strategy for HIV-1 protease dimerization inhibitors.	Purdue University
15056001	4	A phenylnorstatine inhibitor binding to HIV-1 protease: geometry, protonation, and subsite-pocket interactions analyzed at atomic resolution.	Academy of Sciences of The Czech Republic
15027855	30	Countering cooperative effects in protease inhibitors using constrained beta-strand-mimicking templates in focused combinatorial libraries.	The University of Queensland
14613322	12	Dimerization inhibitors of HIV-1 protease based on a bicyclic guanidinium subunit.	Universidad Aut£Noma De Madrid
12459011	94	Relationships between structure and interaction kinetics for HIV-1 protease inhibitors.	Uppsala University
11462972	93	Quinoxalinylethylpyridylthioureas (QXPTs) as potent non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors. Further SAR studies and identification of a novel orally bioavailable hydrazine-based antiviral agent.	Universita' Degli Studi Di Salerno
11428926	37	4-Hydroxy-5,6-dihydropyrones as inhibitors of HIV protease: the effect of heterocyclic substituents at C-6 on antiviral potency and pharmacokinetic parameters.	Pfizer
10753465	8	Conformational selection of inhibitors and substrates by proteolytic enzymes: implications for drug design and polypeptide processing.	University of Queensland
10669559	180	Protease inhibitors: current status and future prospects.	University of Queensland
11000004	16	Synthesis, stability, antiviral activity, and protease-bound structures of substrate-mimicking constrained macrocyclic inhibitors of HIV-1 protease.	The University of Queensland
10978186	45	Identification of MK-944a: a second clinical candidate from the hydroxylaminepentanamide isostere series of HIV protease inhibitors.	Merck Research Laboratories
10821707	26	Modeling of the inhibition of retroviral integrases by styrylquinoline derivatives.	Cnrs Umr 8532
9632374	3	Optimizing the binding of fullerene inhibitors of the HIV-1 protease through predicted increases in hydrophobic desolvation.	University of California
9397180	4	Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease.	Agouron Pharmaceuticals
9258349	12	An orally bioavailable pyrrolinone inhibitor of HIV-1 protease: computational analysis and X-ray crystal structure of the enzyme complex.	University of Pennsylvania
8691444	105	Antiretroviral agents as inhibitors of both human immunodeficiency virus type 1 integrase and protease.	National Cancer Institute-Bethesda
8164249	46	Application of the three-dimensional structures of protein target molecules in structure-based drug design.	Abbott Laboratories
8295217	7	Evaluation of a vitamin-cloaking strategy for oligopeptide therapeutics: biotinylated HIV-1 protease inhibitors.	Upjohn Laboratories
8478908	22	Inhibitors of the protease from human immunodeficiency virus: synthesis, enzyme inhibition, and antiviral activity of a series of compounds containing the dihydroxyethylene transition-state isostere.	Upjohn Laboratories
8355256	11	Peptidomimetic HIV protease inhibitors: phosphate prodrugs with improved biological activities.	Upjohn
8340918	4	Multiple copy simultaneous search and construction of ligands in binding sites: application to inhibitors of HIV-1 aspartic proteinase.	Harvard University
1560443	32	Intriguing structure-activity relations underlie the potent inhibition of HIV protease by norstatine-based peptides.	Syntex Research
1433192	27	New hydroxyethylamine HIV protease inhibitors that suppress viral replication.	University of Wisconsin-Madison
1527792	55	Specific inhibition of HIV-1 protease by boronated porphyrins.	University of California
1875334	16	Inhibitors of the protease from human immunodeficiency virus: design and modeling of a compound containing a dihydroxyethylene isostere insert with high binding affinity and effective antiviral activity.	Upjohn
1875332	33	HIV protease: a novel chemotherapeutic target for AIDS.	Merck Sharp and Dohme Research Laboratories
1766005	5	Examination of HIV-1 protease secondary structure specificity using conformationally constrained inhibitors.	University of Illinois
1956054	27	Novel binding mode of highly potent HIV-proteinase inhibitors incorporating the (R)-hydroxyethylamine isostere.	Roche Products
15006369	7	Crucial amides for dimerization inhibitors of HIV-1 protease.	Purdue University
12067556	8	Structure-based design and synthesis of HIV-1 protease inhibitors employing beta-D-mannopyranoside scaffolds.	University College Dublin
11212098	25	Trifluoromethyl-containing 3-alkoxymethyl- and 3-aryloxymethyl-2-pyridinones are potent inhibitors of HIV-1 non-nucleoside reverse transcriptase.	Dupont Pharmaceuticals
11591519	20	Simplified catechin-gallate inhibitors of HIV-1 reverse transcriptase.	University of Toledo
11549448	2	Design and synthesis of new inhibitors of HIV-1 protease dimerization with conformationally constrained templates.	Kyoto Pharmaceutical University
10386929	10	The sulfonimidamide as a novel transition state analog for aspartic acid and metallo proteases.	The University of Kansas
9871524	10	Structure based design: novel spirocyclic ethers as nonpeptidal P2-ligands for HIV protease inhibitors.	University of Illinois At Chicago
9873718	12	Restricting the flexibility of crosslinked, interfacial peptide inhibitors of HIV-1 protease.	Purdue University
	35	Structure-activity relationships for macrocyclic peptidomimetic inhibitors of HIV-1 protease	TBA
	37	Peptidomimetic inhibitors of human immunodeficiency virus protease (HIV-PR): Design, enzyme binding and selectivity, antiviral efficacy, and cell permeability properties	TBA
	8	Phosphonamidates and phosphonamidate esters as HIV-1 protease inhibitors	TBA
	1	Lack of stereospecificity in the binding of the P2 amino acid of ritonavir to HIV protease	TBA
	5	Synthesis and evaluation of delta lactams as nonpeptide HIV-protease inhibitors	TBA
	14	Synthesis and evaluation of imidazolidinones as nonpeptide HIV-protease inhibitors	TBA
	20	Synthesis and pharmacological evaluation of sulfone substituted HIV protease inhibitors	TBA
	10	Synthesis of irreversible HIV-1 protease inhibitors containing sulfonamide and sulfone as amide bond isosteres	TBA
	2	Synthesis of 7-membered cyclic hydroxyguanidines: Novel HIV-1 protease inhibitors	TBA
	28	Functionalized aliphatic P2/P2′ analogs of HIV-1 protease inhibitor DMP323	TBA
	3	Cyclic urea HIV protease inhibitors containing alkynyl- and alkenyl-tethered heterocycles in the P2 region	TBA
	25	6-Phenyl-6-alkylamido-5,6-dihydro-2H-pyran-2-ones: novel HIV protease inhibitors	TBA
	6	Design, synthesis, and characterization of dipeptide isostere containing cis-epoxide for the irreversible inactivation of HIV protease	TBA
	7	β-Methanesulfonyl-L-valine as a novel, unnatural amino acid surrogate for P2 in the design of HIV protease inhibitors.	TBA
	18	(Hydroxyethyl) sulfonamide HIV-1 Protease inhibitors: Identification of the 2-methylbenzoyl moiety at P-2	TBA
	7	Synthesis and activity of conformationally-constrained macrocyclic norstatine-based inhibitors of HIV protease	TBA
	23	Potent cyclic urea HIV protease inhibitors with benzofused heterocycles as P2/P2′ groups	TBA
	8	Design and synthesis of novel, pseudo C2 symmetric inhibitors of HIV protease	TBA
	15	Aromatic P1 replacements for the highly potent HIV-1 protease inhibitor CRIXIVAN®	TBA
	11	Synthesis of (+)-biotin derivatives as HIV-1 protease inhibitors	TBA
	37	Nonpeptidic HIV protease inhibitors: 3-(S-benzyl substituted)-4-hydroxy-6-(phenyl substituted)-2H-pyran-2-one with an inverse mode of binding	TBA
	32	A topliss tree analysis of the HIV-protease inhibitory activity of 6-phenyl-4-hydroxy-pyran-2-ones	TBA
	17	Structure-based drug design of nonpeptidic P2 substituents for HIV-1 protease inhibitors	TBA
	9	Isophthalic acid derivatives: amino acid surrogates for the inhibition of HIV-1 protease	TBA
	12	A systematic study of P1–P3 spanning sidechains for the inhibition of HIV-1 protease	TBA
	29	2-Heterocyclic indole-3-sulfones as inhibitors of HIV-1 reverse transcriptase	TBA
	14	Aminodiol HIV protease inhibitors. 2. 1,1-Dimethyl-2-hydroxyethyl carbamate derivatives with enhanced potency	TBA
	4	A bis-[N-3-(1-hydroxy-1-methyl-ethyl)-benzyl)-cyclic urea as a HIV protease inhibitor	TBA
	7	Ly316340: A potent HIV-1 protease inhibitor containing a high affinity octahydrothienopyridine hydroxyethylamine isostere	TBA
	30	Evaluation of substituted benzamides as P2 ligands for symmetry-based inhibitors of HIV protease	TBA
	15	Structure-based design of achiral anthranilamides as P2/P2′ surrogates for symmetry-based HIV protease inhibitors: design, synthesis, X-ray structure, enzyme inhibition and antiviral activity	TBA
	13	Thiophene derivatives as extremely high affinity P3′ ligands for the hydroxyethylpiperazine class of HIV-1 protease inhibitors	TBA
	9	Substituted alkylpyridines as P3′ ligands for the hydroxyethylpiperazine class of HIV-1 protease inhibitors: Improved pharmacokinetic profiles	TBA
	10	Rational design of irreversible, pseudo-C2-symmetric hiv-1 protease inhibitors	TBA
	23	α-hydroxyamide derived aminodiols as potent inhibitors of hiv protease	TBA
	7	Symmetry-based HIV Protease inhibitors: rational design of 2-methylbenzamides as novel P2/P2′ ligands	TBA
	14	Cyclic sulfone-3-carboxamides as novel P2-ligands for Ro 31-8959 based HIV-1 protease inhibitors	TBA
	2	Synthesis of C2-symmetric inhibitors of the HIV-1 protease, with N,N′-substituted ethylenediamide and ethylenediamine linkers.	TBA
	7	Design, structure activity and x-ray crystallographic studies of pseudosymmetrical nonpeptidyl HIV-1 protease inhibitors	TBA
	7	Conformationally constrained HIV-1 protease inhibitors	TBA
	13	Novel, extended transition state mimic in HIV-1 protease inhibitors with peripheral C-2-symmetry	TBA
	13	Synthesis and evaluation of pyridyl analogs of L-735,524: Potent HIV-1 protease inhibitors	TBA
	6	Carbocyclic analogues of hydroxyethylamine containing inhibitors of HIV proteinase	TBA
	8	Non-peptide-based inhibitors of human immunodeficiency virus-1 protease	TBA
	14	Beneficial replacement of the P1 phenylalanine side chain in HIV-1 protease inhibitors of the difluorostatone type	TBA
	23	A new hydroxyethylamine class of HIV-1 protease inhibitors with high antiviral potency and oral bioavailability	TBA
	19	Design, synthesis, and activity of conformationally-constrained macrocyclic peptide-based inhibitors of HIV protease	TBA
	13	Novel conformationally constrained HIV-1 protease inhibitors: rational design, enzyme inhibition, and X-ray structure of an enzyme-inhibtor complex	TBA
	14	D-amino acids as novel P2/P3 ligands for inhibitors of HIV-1 protease	TBA
	7	New dipeptide isosteres useful for the inhibition of HIV-1 protease	TBA
	1	Peptoid mimics of a C2-symmetric inhibitor of the HIV-1 protease.	TBA
	4	De novo design of nonpeptidic HIV-1 protease inhibitors: Incorporation of structural water.	TBA
	15	Increased antiviral activity of HIV protease inhibitors of the difluorostatone type bearing (R)-valinol derivatives as novel c-termini	TBA
	8	Inhibition of human immunodeficiency virus-1 protease by a C2-symmetrical phosphinic acid amide	TBA
	3	A concise enantioselective synthesis of rans-olefin dipeptide isosteres	TBA
	16	Synthesis and biological evaluation of a series of HIV-1 protease inhibitors	TBA
	17	Structure activity studies on pseudo-symmetrical HIV-1 protease inhibitors	TBA
	5	The design and synthesis of novel hydroxyproline inhibitors of HIV-1 proteinase	TBA
	22	Difunctional enols of N-protected amino acids as low molecular weight and novel inhibitors of HIV-1 protease.	TBA
	10	Novel dimeric penicillin derived inhibitors of HIV-1 proteinase: interaction with the catalytic aspartates	TBA
	17	Short and unexpectedly potent difluorostatone type inhibitors of HIV-1 protease	TBA
	22	Novel pseudosymmetric inhibitors of HIV-1 protease	TBA
	8	Nonpeptide HIV protease inhibitors designed to replace a bound water	TBA
17181152	17	Rapid discovery and structure-activity profiling of novel inhibitors of human immunodeficiency virus type 1 protease enabled by the copper(I)-catalyzed synthesis of 1,2,3-triazoles and their further functionalization.	The Scripps Research Institute
16970402	8	HIV-1 protease mutations and inhibitor modifications monitored on a series of complexes. Structural basis for the effect of the A71V mutation on the active site.	Academy of Sciences of The Czech Republic
16854071	10	Molecular tongs containing amino acid mimetic fragments: new inhibitors of wild-type and mutated HIV-1 protease dimerization.	Paris-Sud University
16335934	10	A new class of HIV-1 protease inhibitors containing a tertiary alcohol in the transition-state mimicking scaffold.	Uppsala University
16203141	5	Synthesis and activity of N-acyl azacyclic urea HIV-1 protease inhibitors with high potency against multiple drug resistant viral strains.	Abbott Laboratories
15923115	6	Design, synthesis, and biological evaluation of novel 4-hydroxypyrone derivatives as HIV-1 protease inhibitors.	Peking University
15893929	3	Beta-lactam compounds as apparently uncompetitive inhibitors of HIV-1 protease.	University of Debrecen
15771440	3	Design of HIV-1 protease inhibitors active on multidrug-resistant virus.	Tibotec
15582426	3	New 2-bromomethyl-8-substituted-benzo[c]chromen-6-ones. Synthesis and biological properties.	University of The Mediterranean
15566308	32	New constrained"molecular tongs" designed to dissociate HIV-1 protease dimer.	Paris-Sud University
15509178	37	Efficient evaluation of binding free energy using continuum electrostatics solvation.	University of ZüRich
15380231	2	Facile incorporation of urea pseudopeptides into protease substrate analogue inhibitors.	Purdue University
15225729	5	Synthesis and antiviral activity of P1' arylsulfonamide azacyclic urea HIV protease inhibitors.	Abbott Laboratories
15149657	33	Novel nonpeptidic inhibitors of HIV-1 protease obtained via a new multicomponent chemistry strategy.	Morphochem
15139755	3	BREED: Generating novel inhibitors through hybridization of known ligands. Application to CDK2, p38, and HIV protease.	Vertex Pharmaceuticals
12852755	27	l-2',3'-Didehydro-2',3'-dideoxy-3'-fluoronucleosides: synthesis, anti-HIV activity, chemical and enzymatic stability, and mechanism of resistance.	The University of Georgia
12729673	39	Design and synthesis of highly potent HIV protease inhibitors with activity against resistant virus.	Merck Research Laboratories
12699395	5	Reduction of peptide character of HIV protease inhibitors that exhibit nanomolar potency against multidrug resistant HIV-1 strains.	Kyoto University
12639540	10	Synthesis, antiviral activity and pharmacokinetics of P1/P1' substituted 3-aminoindazole cyclic urea HIV protease inhibitors.	Bristol-Myers Squibb
12477350	47	Metal-dependent inhibition of HIV-1 integrase.	University of Southern California
12467624	9	Design and synthesis of pseudo-symmetric HIV protease inhibitors containing a novel hydroxymethylcarbonyl (HMC)-hydrazide isostere.	Kyoto Pharmaceutical University
12270162	4	Combinatorial library of indinavir analogues: replacement for the aminoindanol at P2'.	Merck Research Laboratories
12161148	17	Synthesis and activity of novel HIV protease inhibitors with improved potency against multiple PI-resistant viral strains.	Merck Research Laboratories
12161147	5	Indinavir analogues with blocked metabolism sites as HIV protease inhibitors with improved pharmacological profiles and high potency against PI-resistant viral strains.	Merck Research Laboratories
12109915	5	Synthesis and antiviral activity of new anti-HIV amprenavir bioisosteres.	University of The Mediterranean
11844665	38	A combinatorial library of indinavir analogues and its in vitro and in vivo studies.	Merck Research Laboratories
11784138	36	Elucidating the inhibiting mode of AHPBA derivatives against HIV-1 protease and building predictive 3D-QSAR models.	Chinese Academy of Sciences
32672965	44	Structural Analysis of Potent Hybrid HIV-1 Protease Inhibitors Containing Bis-tetrahydrofuran in a Pseudosymmetric Dipeptide Isostere.	University of Massachusetts Medical School
32690263	29	Design and biological evaluation of novel HIV-1 protease inhibitors with isopropanol as P1' ligand to enhance binding with S1' subsite.	Chinese Academy of Medical Science and Peking Union Medical College
11378352	3	Synthesis and antiviral activities of the major metabolites of the HIV protease inhibitor ABT-378 (Lopinavir).	Abbott Laboratories
32551001	25	Novel HIV-1 Protease Inhibitors with Morpholine as the P2 Ligand to Enhance Activity against DRV-Resistant Variants.	Chinese Academy of Medical Science and Peking Union Medical College
32057582	29	Design, synthesis and biological evaluation of HIV-1 protease inhibitors with morpholine derivatives as P2 ligands in combination with cyclopropyl as P1' ligand.	Jinzhou Medical University
11206463	44	Design, synthesis, and biological evaluation of HIV/FIV protease inhibitors incorporating a conformationally constrained macrocycle with a small P3' residue.	The Scripps Research Institute
11128638	7	6-Hydroxy-1,3-dioxin-4-ones as non-peptidic HIV protease inhibitors.	Institute of Science & Technology
10987441	10	Use of proline bioisosteres in potential HIV protease inhibitors: phenylalanine-2-thiophenoxy-3-pyrrolidinone: synthesis and anti-HIV evaluation.	Université
10915042	3	Combinatorial diversification of indinavir: in vivo mixture dosing of an HIV protease inhibitor library.	Merck Research Laboratories
10866387	1	'Double-Drugs'--a new class of prodrug form of an HIV protease inhibitor conjugated with a reverse transcriptase inhibitor by a spontaneously cleavable linker.	Kyoto Pharmaceutical University
10821715	34	A new class of HIV-1 integrase inhibitors: the 3,3,3', 3'-tetramethyl-1,1'-spirobi(indan)-5,5',6,6'-tetrol family.	University of California
10579836	7	Synthesis and biological evaluation of the first N-alkyl cage dimeric 4-aryl-1,4-dihydropyridines as novel nonpeptidic HIV-1 protease inhibitors.	Martin-Luther-University Halle-Wittenberg
10576691	11	Unsymmetrical cyclic ureas as HIV-1 protease inhibitors: novel biaryl indazoles as P2/P2' substituents.	Dupont Pharmaceuticals
10514275	7	Inhibitors of the C(2)-symmetric HIV-1 protease: nonsymmetric binding of a symmetric cyclic sulfamide with ketoxime groups in the P2/P2' side chains.	Uppsala University
10465557	11	Increased antiviral activity of cyclic urea HIV protease inhibitors by modifying the P1/P1' substituents.	Dupont Pharmaceuticals
10450973	21	4-hydroxy-5,6-dihydro-2H-pyran-2-ones.3. Bicyclic and hetero-aromatic ring systems as 3-position scaffolds to bind to S1' and S2' of the HIV-1 protease enzyme.	Warner-Lambert
10386921	33	Nonpeptidic HIV protease inhibitors: 6-alkyl-5,6-dihydropyran-2-ones possessing achiral 3-(4-amino/carboxamide-2-t-butyl,5-methylphenyl thio) moiety: antiviral activities and pharmacokinetic properties.	Warner-Lambert
10328309	3	Structure-based design of diaminopyranosides as a novel inhibitor core unit of HIV proteases.	Biomolecular Engineering Research Institute
10206539	1	A new class of anti-HIV agents: synthesis and activity of conjugates of HIV protease inhibitors with a reverse transcriptase inhibitor.	Kyoto Pharmaceutical University
10090778	9	Design, synthesis, and evaluation of conformationally constrained tongs, new inhibitors of HIV-1 protease dimerization.	Université
9934485	8	Design and synthesis of novel conformationally restricted HIV protease inhibitors.	Vertex Pharmaceuticals
9934484	32	Design, synthesis, and conformational analysis of a novel series of HIV protease inhibitors.	Vertex Pharmaceuticals
9934481	9	Tricyclic ureas: a new class of HIV-1 protease inhibitors.	Dupont Pharmaceuticals
9934467	27	Unsymmetric nonpeptidic HIV protease inhibitors containing anthranilamide as a P2' ligand.	Aids Drug Screening and Development Laboratory
9925730	118	Three-dimensional quantitative structure-activity relationship study on cyclic urea derivatives as HIV-1 protease inhibitors: application of comparative molecular field analysis.	Lindsley F. Kimball Research Institute
9873554	3	NMR and topochemical studies of peptidomimetic HIV-I protease inhibitors containing a cis-epoxide amide isostere.	Biotech Research Institute
9873448	1	Synthesis and anti-HIV activities of symmetrical N1,N3-dibenzyl-2-hydroxy-propane derivatives.	Université
9871742	11	Non-peptidic HIV protease inhibitors: C2-symmetry-based design of bis-sulfonamide dihydropyrones.	Pharmacia & Upjohn
9871586	7	Endothiopeptide inhibitors of HIV-1 protease.	Purdue University
9871548	17	The synthesis and evaluation of cyclic ureas as HIV protease inhibitors: modifications of the P1/P1' residues.	Dupont Pharmaceuticals
9871528	9	Potent cyclic urea HIV protease inhibitors with 3-aminoindazole P2/P2' groups.	Dupont Pharmaceuticals
9871514	16	Novel HIV-protease inhibitors containing beta-hydroxyether and -thioether dipeptide isostere surrogates: modification of the P3 ligand.	Schering-Plough Research Institute
9748353	13	Design and synthesis of new potent C2-symmetric HIV-1 protease inhibitors. Use of L-mannaric acid as a peptidomimetic scaffold.	LinköPing University
9632373	52	Nonsymmetric P2/P2' cyclic urea HIV protease inhibitors. Structure-activity relationship, bioavailability, and resistance profile of monoindazole-substituted P2 analogues.	Dupont Pharmaceuticals
9622543	26	Cyclic HIV protease inhibitors: design and synthesis of orally bioavailable, pyrazole P2/P2' cyclic ureas with improved potency.	Dupont Pharmaceuticals
9572884	7	Cyclopropane-derived peptidomimetics. Design, synthesis, evaluation, and structure of novel HIV-1 protease inhibitors.	National Cancer Institute-Frederick
9484509	12	Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy.	Abbott Laboratories
9406598	24	Nonsymmetrically substituted cyclic urea HIV protease inhibitors.	Dupont Pharmaceuticals
31188592	39	Why Some Targets Benefit from beyond Rule of Five Drugs.	Boston University
9003516	17	Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV.	Dupont Pharmaceuticals
8917652	23	Structure-based design of HIV protease inhibitors: 5,6-dihydro-4-hydroxy-2-pyrones as effective, nonpeptidic inhibitors.	Pharmacia & Upjohn
8863807	71	HIV protease inhibitory bis-benzamide cyclic ureas: a quantitative structure-activity relationship analysis.	Dupont Pharmaceuticals
8831779	22	Cycloalkylpyranones and cycloalkyldihydropyrones as HIV protease inhibitors: exploring the impact of ring size on structure-activity relationships.	Pharmacia and Upjohn
8784440	3	New series of potent, orally bioavailable, non-peptidic cyclic sulfones as HIV-1 protease inhibitors.	Gilead Sciences
8709096	26	Pyrrolobenzothiazepinones and pyrrolobenzoxazepinones: novel and specific non-nucleoside HIV-1 reverse transcriptase inhibitors with antiviral activity.	Universitá
8676334	9	Betulinic acid and dihydrobetulinic acid derivatives as potent anti-HIV agents.	University of North Carolina At Chapel Hill
8632437	8	Synthesis, chromatographic resolution, and anti-human immunodeficiency virus activity of (+/-)-calanolide A and its enantiomers.	Medichem Research
8426362	46	Symmetry-based inhibitors of HIV protease. Structure-activity studies of acylated 2,4-diamino-1,5-diphenyl-3-hydroxypentane and 2,5-diamino-1,6-diphenylhexane-3,4-diol.	Abbott Laboratories
8360876	9	A novel constrained reduced-amide inhibitor of HIV-1 protease derived from the sequential incorporation of gamma-turn mimetics into a model substrate.	Smithkline Beecham Pharmaceuticals
8230097	7	A series of penicillin-derived C2-symmetric inhibitors of HIV-1 proteinase: structural and modeling studies.	Glaxo Group Research
8164256	6	Calculation of relative differences in the binding free energies of HIV1 protease inhibitors: a thermodynamic cycle perturbation approach.	Agouron Pharmaceuticals
8126707	18	Haloperidol-based irreversible inhibitors of the HIV-1 and HIV-2 proteases.	University of California
8057296	4	Structure-based design of HIV-1 protease inhibitors: replacement of two amides and a 10 pi-aromatic system by a fused bis-tetrahydrofuran.	Merck Research Laboratories
7966131	34	Synthesis and structure-activity relationships of a series of penicillin-derived HIV proteinase inhibitors: heterocyclic ring systems containing P1' and P2' substituents.	Glaxo Research and Development
7966128	2	Design, synthesis, and conformational analysis of a novel macrocyclic HIV-protease inhibitor.	Marion Merrell Dow Research Institute
7932573	19	L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor.	Merck Research Laboratories
7932533	11	Rational design, synthesis, and crystallographic analysis of a hydroxyethylene-based HIV-1 protease inhibitor containing a heterocyclic P1'--P2' amide bond isostere.	Smithkline Beecham Pharmaceuticals
7861404	29	Inhibitors of HIV-1 protease containing the novel and potent (R)-(hydroxyethyl)sulfonamide isostere.	Searle Discovery Research
7853337	12	Cosalane analogues with enhanced potencies as inhibitors of HIV-1 protease and integrase.	Purdue University
7830273	49	A priori prediction of activity for HIV-1 protease inhibitors employing energy minimization in the active site.	Merck Research Laboratories
7650677	2	A check on rational drug design: crystal structure of a complex of human immunodeficiency virus type 1 protease with a novel gamma-turn mimetic inhibitor.	Smithkline Beecham Pharmaceuticals
7636862	8	Synthetic chemical diversity: solid phase synthesis of libraries of C2 symmetric inhibitors of HIV protease containing diamino diol and diamino alcohol cores.	Abbott Laboratories
7543578	6	Anti-AIDS (acquired immune deficiency syndrome) agents. 17. New brominated hexahydroxybiphenyl derivatives as potent anti-HIV agents.	University of North Carolina At Chapel Hill
7540208	10	Thiadiazole derivatives: highly potent and specific HIV-1 reverse transcriptase inhibitors.	Tosoh
7520080	18	Synthesis of naphthalenesulfonic acid small molecules as selective inhibitors of the DNA polymerase and ribonuclease H activities of HIV-1 reverse transcriptase.	College of Pharmacy
7473573	47	Structure-based design of nonpeptidic HIV protease inhibitors from a cyclooctylpyranone lead structure.	Upjohn Laboratories
11831910	60	Computational studies on tetrahydropyrimidine-2-one HIV-1 protease inhibitors: improving three-dimensional quantitative structure-activity relationship comparative molecular field analysis models by inclusion of calculated inhibitor- and receptor-based properties.	University of Missouri-St. Louis
12061879	44	SMall Molecule Growth 2001 (SMoG2001): an improved knowledge-based scoring function for protein-ligand interactions.	Harvard University
2213822	12	Structure-based, C2 symmetric inhibitors of HIV protease.	Abbott Laboratories
2184237	17	Hydroxyethylamine analogues of the p17/p24 substrate cleavage site are tight-binding inhibitors of HIV protease.	University of Wisconsin-Madison
2002464	16	Effect of hydroxyl group configuration in hydroxyethylamine dipeptide isosteres on HIV protease inhibition. Evidence for multiple binding modes.	University of Wisconsin-Madison
1635054	17	A series of potent HIV-1 protease inhibitors containing a hydroxyethyl secondary amine transition state isostere: synthesis, enzyme inhibition, and antiviral activity.	Merck Research Laboratories
1501235	11	Penicillin derived C2-symmetric dimers as novel inhibitors of HIV-1 proteinase.	Glaxo Group Research
15189032	66	Design and synthesis of potent inhibitors of the malaria aspartyl proteases plasmepsin I and II. Use of solid-phase synthesis to explore novel statine motifs.	Linkoping University
9871543	17	Synthesis of C2 alkynylated purines, a new family of potent inhibitors of cyclin-dependent kinases.	Institut Curie
15546737	59	Aminoimidazo[1,2-a]pyridines as a new structural class of cyclin-dependent kinase inhibitors. Part 1: Design, synthesis, and biological evaluation.	Avenida De La Industria
15745832	35	Further studies on ethenyl and ethynyl-4-phenylamino-3-quinolinecarbonitriles: identification of a subnanomolar Src kinase inhibitor.	Wyeth-Ayerst Research
11078204	19	Inhibitors of src tyrosine kinase: the preparation and structure-activity relationship of 4-anilino-3-cyanoquinolines and 4-anilinoquinazolines.	Wyeth-Ayerst Research